A study in the Journal of the American Medical Association indicates that ubrogepant demonstrated greater rates of pain and symptom relief from migraine compared with a placebo. More than 20% of participants in a large-scale clinical trial reported being pain-free within 2 hours and more than 34% were relieved of the most severe symptoms associated with migraines when administered the drug, compared with 14% and 27%, respectively, from the placebo. These symptoms include light and noise sensitivity. Richard B. Lipton, MD, director of the Montefiore Headache Center in New York, who led the study, observes: “Migraine is the second leading cause of disability, and we need new acute treatments that are efficacious, safe, and tolerable.” Lipton is a consultant for Allergan, the pharmaceutical company that sponsored the trial. Ubrogepant is currently pending approval by the FDA. The drug targets a protein called calcitonin gene-related peptide, which is involved in the transmission of pain.
Archives
Top Posts
- CGRP Migraine Monoclonal Injections: proceed with caution" from Dr. Robbins, M.D.
- CGRP QUESTIONS/ANSWERS
- NHL Star Chris Pronger Has a Headache
- New Butalbital Product(similar to Fioricet/Fiorinal/Esgic/Phrenilin)
- CGRP AND SIDE EFFECTS: LETTER IN ‘HEADACHE”
- Heading the Ball Causes Brain Damage
- "27 Foods That Can Give You More Energy" from Healthline
- "Pathologic Differences Between Migraine With or Without Aura" from Neurology Advisor
Topics
adolescents
Alzheimer's disease
Alzheimers
anxiety
back pain
blood pressure
botox
brain
caffeine
children
chronic migraine
chronic pain
cluster headache
concussion
concussions
COVID-19
dementia
depression
diet
exercise
fibromyalgia
Headache
headache blog
headaches
health
heart disease
meditation
men
migraine
migraine headache
migraine headaches
migraines
migraine triggers
migraine with aura
pain
physical activity
sleep
stress
stroke
triggers
triptans
vitamin D
walking
women
yoga